-
Hong Kong Medical Journal = Xianggang... Dec 2014Lymphoedema is a chronic, progressive condition. There is no cure but it is most easily managed with early recognition and therapy; those who do not have treatment tend... (Review)
Review
Lymphoedema is a chronic, progressive condition. There is no cure but it is most easily managed with early recognition and therapy; those who do not have treatment tend to worsen rapidly and advanced disease is more difficult to treat than early disease. Surgery for lymphoedema is often regarded as a last resort but traditional excisional techniques that have been slightly modified for modern practice have shown good results, whilst newer microsurgical reconstruction techniques show promise although long-term results are lacking. This report provides an update on the therapy of lymphoedema.
Topics: Humans; Lymphedema; Minimally Invasive Surgical Procedures; Physical Therapy Modalities
PubMed: 25170053
DOI: 10.12809/hkmj134116 -
Ugeskrift For Laeger Jun 2018Lymphoedema is a frequent condition after surgical treatment for breast cancer. Lymphoedema causes great discomfort for the patients and is primarily treated... (Review)
Review
Lymphoedema is a frequent condition after surgical treatment for breast cancer. Lymphoedema causes great discomfort for the patients and is primarily treated conservatively with compression garments and physical therapy. Recently, surgical interventions have gained popularity in the form of lympho-lymphatic anastomoses, lympho-venous anastomoses and autologous lymph node transplantation, either as stand-alone treatment or in combination with secondary breast reconstruction. In Denmark, lympho-venous anastomoses is currently the primary surgical treatment for lymphoedema.
Topics: Algorithms; Anastomosis, Surgical; Humans; Lipectomy; Lymph Nodes; Lymphatic Vessels; Lymphedema; Transplantation, Autologous; Veins
PubMed: 29938631
DOI: No ID Found -
Indian Journal of Dermatology,... 2019
Topics: Adult; Humans; Lymphedema; Male; Papilloma
PubMed: 29697069
DOI: 10.4103/ijdvl.IJDVL_763_17 -
Current Oncology (Toronto, Ont.) Apr 2023Lymphedema is a chronic progressive disorder that significantly compromises patients' quality of life. In Western countries, it often results from cancer treatment, as... (Review)
Review
Lymphedema is a chronic progressive disorder that significantly compromises patients' quality of life. In Western countries, it often results from cancer treatment, as in the case of post-radical prostatectomy lymphedema, where it can affect up to 20% of patients, with a significant disease burden. Traditionally, diagnosis, assessment of severity, and management of disease have relied on clinical assessment. In this landscape, physical and conservative treatments, including bandages and lymphatic drainage have shown limited results. Recent advances in imaging technology are revolutionizing the approach to this disorder: magnetic resonance imaging has shown satisfactory results in differential diagnosis, quantitative classification of severity, and most appropriate treatment planning. Further innovations in microsurgical techniques, based on the use of indocyanine green to map lymphatic vessels during surgery, have improved the efficacy of secondary LE treatment and led to the development of new surgical approaches. Physiologic surgical interventions, including lymphovenous anastomosis (LVA) and vascularized lymph node transplant (VLNT), are going to face widespread diffusion. A combined approach to microsurgical treatment provides the best results: LVA is effective in promoting lymphatic drainage, bridging VLNT delayed lymphangiogenic and immunological effects in the lymphatic impairment site. Simultaneous VLNT and LVA are safe and effective for patients with both early and advanced stages of post-prostatectomy LE. A new perspective is now represented by the combination of microsurgical treatments with the positioning of nano fibrillar collagen scaffolds (BioBridgeTM) to favor restoring the lymphatic function, allowing for improved and sustained volume reduction. In this narrative review, we proposed an overview of new strategies for diagnosing and treating post-prostatectomy lymphedema to get the most appropriate and successful patient treatment with an overview of the main artificial intelligence applications in the prevention, diagnosis, and management of lymphedema.
Topics: Male; Humans; Quality of Life; Artificial Intelligence; Lymphedema; Lymphatic Vessels; Prostatectomy
PubMed: 37232799
DOI: 10.3390/curroncol30050341 -
Advances in Wound Care Aug 2022Secondary lymphedema is a debilitating disease caused by lymphatic dysfunction characterized by chronic swelling, dysregulated inflammation, disfigurement, and... (Review)
Review
Secondary lymphedema is a debilitating disease caused by lymphatic dysfunction characterized by chronic swelling, dysregulated inflammation, disfigurement, and compromised wound healing. Since there is no effective cure, animal model systems that support basic science research into the mechanisms of secondary lymphedema are critical to advancing the field. Over the last decade, lymphatic research has led to the improvement of existing animal lymphedema models and the establishment of new models. Although an ideal model does not exist, it is important to consider the strengths and limitations of currently available options. In a systematic review adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we present recent developments in the field of animal lymphedema models and provide a concise comparison of ease, cost, reliability, and clinical translatability. The incidence of secondary lymphedema is increasing, and there is no gold standard of treatment or cure for secondary lymphedema. As we iterate and create animal models that more closely characterize human lymphedema, we can achieve a deeper understanding of the pathophysiology and potentially develop effective therapeutics for patients.
Topics: Animals; Disease Models, Animal; Humans; Lymphatic System; Lymphatic Vessels; Lymphedema; Reproducibility of Results
PubMed: 34128396
DOI: 10.1089/wound.2021.0033 -
CA: a Cancer Journal For Clinicians 2009
Topics: Humans; Lymphedema
PubMed: 19147866
DOI: 10.3322/caac.20007 -
British Medical Journal (Clinical... Aug 1986
Topics: Humans; Lymphedema
PubMed: 3089515
DOI: 10.1136/bmj.293.6543.347 -
Oncology (Williston Park, N.Y.) Mar 2012Lymphedema is a feared complication of cancer treatment and one that negatively impacts survivorship. The incidence of breast cancer-related lymphedema ranges from 6% to... (Review)
Review
Lymphedema is a feared complication of cancer treatment and one that negatively impacts survivorship. The incidence of breast cancer-related lymphedema ranges from 6% to 70%, but lymphedema may be a common and under-reported morbidity. No standard guidelines for its diagnosis and assessment exist. Although the true etiology of lymphedema remains unknown, radiation, chemotherapy, type of breast surgery, and extent of axillary surgery are commonly cited risk factors. However, the relationship between the number of nodes removed and the risk of lymphedema is not clearly correlated. Clinical trials are focusing on ways to reduce the need for axillary dissection even in the setting of a positive sentinel node, to help minimize axillary morbidity. Risk-reduction practices, including avoidance of skin puncture and blood pressures in the ipsilateral upper extremity, and precautionary behaviors such as wearing compression garments during air travel continue to be advocated by the medical and survivor communities, despite a lack of rigorous evidence supporting their benefit. Emerging data support exercise in at-risk and affected women with lymphedema when started gradually and increased cautiously.
Topics: Breast Neoplasms; Female; Humans; Lymphedema
PubMed: 22545305
DOI: No ID Found -
CA: a Cancer Journal For Clinicians 1982
Topics: Female; Humans; Lymphangiosarcoma; Lymphedema; Mastectomy; Postoperative Care
PubMed: 6799167
DOI: 10.3322/canjclin.32.1.63-a -
International Journal of Molecular... Apr 2023Secondary lymphedema is caused by lymphatic insufficiency (lymphatic drainage failure) following lymph node dissection during the surgical treatment or radiation therapy... (Review)
Review
Secondary lymphedema is caused by lymphatic insufficiency (lymphatic drainage failure) following lymph node dissection during the surgical treatment or radiation therapy of breast or pelvic cancer. The clinical problems associated with lymphedema are reduced quality of life in terms of appearance and function, as well as the development of skin ulcers, recurrent pain, and infection. Currently, countermeasures against lymphedema are mainly physical therapy such as lymphatic massage, elastic stockings, and skin care, and there is no effective and fundamental treatment with a highly recommended grade. Therefore, there is a need for the development of a fundamental novel treatment for intractable lymphedema. Therapeutic lymphangiogenesis, which has been attracting attention in recent years, is a treatment concept that reconstructs the fragmented lymphatic network to recover lymphatic vessel function and is revolutionary to be a fundamental cure. This review focuses on the translational research of therapeutic lymphangiogenesis for lymphedema and outlines the current status and prospects in the development of therapeutic applications.
Topics: Humans; Lymph Node Excision; Lymphangiogenesis; Lymphatic Vessels; Lymphedema; Translational Research, Biomedical; Animals
PubMed: 37175479
DOI: 10.3390/ijms24097774